The study compared three groups of drugs for type 2 diabetes – SGLT2 inhibitors, GLP-1 receptor agonists and DPP4 inhibitors – in terms of their effect on the risk of hypomagnesemia (lack of magnesium in the blood). The research included almost 1.4 million patients from a multi-institutional database and followed them until March 2025. The main finding was that patients taking SGLT2 inhibitors had a 20% lower risk of hypomagnesemia compared to patients on DPP4 inhibitors (hazard ratio 0.80) and a 10% lower risk compared to patients on GLP-1 agonists (hazard ratio 0.90). Similarly, patients on GLP-1 agonists had an 11% lower risk of hypomagnesemia than those on DPP4 inhibitors (hazard ratio 0.89). These results were consistent for individual drugs within each group. The authors concluded that SGLT2 inhibitors and GLP-1 agonists may be a better choice for patients at risk of hypomagnesemia compared to DPP4 inhibitors.